@article{article, title  = {{Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with <i>FGFR3/2</i> alterations (<i>alt</i>) in THOR-2: Cohort 2 interim analysis results.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{https://doi.org/10.1200/jco.2023.41.6_suppl.503 }},

 year = {{2023}},

 month = {{2}},

 author = {{Catto JWF and Tran B and Master VA and Roupret M and Pignot G and Tubaro A and Shimizu N and Vasdev N and Gschwend JE and Loriot Y and Nishiyama H et al}},

 doi = {{10.1200/jco.2023.41.6_suppl.503}},

 volume = {{41}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{6_suppl}},

 pages = {{503-503}},

 note = {{Accessed on 2025/10/31}}}